Thalidomide treatment down-regulates SDF-1 alpha and CXCR4 expression in multiple myeloma patients


Autoria(s): OLIVEIRA, Adriana Morgan; MARIA, Durvanei Augusto; METZGER, Martin; LINARDI, Carnila; GIORGI, Ricardo Rodrigues; MOURA, Fernanda; MARTINEZ, Gracia Aparecida; BYDLOWSKI, Sergio Paulo; NOVAK, Estela Maria
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

The chemokine stromal-derived factor-1 alpha (SDF-1 alpha) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple myeloma. Here, we show that the expression of SDF-1 alpha and CXCR4 was significantly down-regulated in patients treated with thalidomide (n = 10) as compared to newly diagnosed MM patients (n = 31) and MM patients treated with other drugs (n = 38). SDF-1 alpha and CXCR4 expression was also significantly decreased in a RPMI 8226 cell line treated with 10 and 20 mu mol/L of thalidomide. Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1 alpha in multiple myeloma. (c) 2008 Elsevier Ltd. All rights reserved.

Identificador

LEUKEMIA RESEARCH, v.33, n.7, p.970-973, 2009

0145-2126

http://producao.usp.br/handle/BDPI/21597

10.1016/j.leukres.2008.09.018

http://dx.doi.org/10.1016/j.leukres.2008.09.018

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

Relação

Leukemia Research

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #Chemokine receptors #SDF-1 alpha #CXCR4 #Multiple myeloma #Thalidomide #Immunomodulation #NF-KAPPA-B #CELLS #MECHANISMS #MIGRATION #SDF-1 #Oncology #Hematology
Tipo

article

original article

publishedVersion